Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Crinetics Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Crinetics Pharmaceuticals, Inc.’s stock price such as:

• Crinetics Pharmaceuticals, Inc.’s current stock price and volume
• Why Crinetics Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for CRNX from analysts
• CRNX’s stock price momentum as measured by its relative strength

About Crinetics Pharmaceuticals, Inc. (CRNX)

Before we jump into Crinetics Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Want to learn more about Crinetics Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Crinetics Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Crinetics Pharmaceuticals, Inc.’s stock price was $83.520.

Crinetics Pharmaceuticals, Inc. is down 0.13% from its previous closing price of $83.630.

During the last market session, Crinetics Pharmaceuticals, Inc.’s stock traded between $83.470 and $83.800. Currently, there are approximately 104.10 million shares outstanding for Crinetics Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Crinetics Pharmaceuticals, Inc. Stock Price History

Crinetics Pharmaceuticals, Inc.’s (CRNX) price is currently up 123.2% so far this month.

During the month of July, Crinetics Pharmaceuticals, Inc.’s stock price has reached a high of $84.000 and a low of $37.365.

Over the last year, Crinetics Pharmaceuticals, Inc. has hit prices as high as $84.000 and as low as $25.830. Year to date, Crinetics Pharmaceuticals, Inc.’s stock is up 79.42%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Crinetics Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Crinetics Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Crinetics Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Crinetics Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Crinetics Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Crinetics Pharmaceuticals, Inc. (CRNX) by visiting AAII Stock Evaluator.

Relative Price Strength of Crinetics Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Crinetics Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 48.34%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Crinetics Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Crinetics Pharmaceuticals, Inc. Stock Price: Bottom Line

As of July 31, 2026, Crinetics Pharmaceuticals, Inc.’s stock price is $83.520, which is down 0.13% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Crinetics Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.